Prevalence of protective antibody against hepatitis B virus in HIV-infected children with immune recovery after highly active antiretroviral therapy
|
|
- Wilfred Watts
- 5 years ago
- Views:
Transcription
1 Vaccine 24 (2006) Prevalence of protective antibody against hepatitis B virus in HIV-infected children with immune recovery after highly active antiretroviral therapy Sudawan Siriaksorn a, Thanyawee Puthanakit a,, Thira Sirisanthana b, Virat Sirisanthana a a Department of Pediatrics, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand b Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand Received 10 October 2005; received in revised form 6 December 2005; accepted 21 January 2006 Available online 6 February 2006 Abstract HIV-infected children had a lower seroconversion rate to hepatitis B immunization and a more rapid antibody decline when compared to healthy children. Whether re-immunization or additional booster dose is necessary after immune recovery remains unknown. This study was conducted to determine the prevalence of hepatitis B virus protective antibody in HIV-infected children with immune recovery after highly active antiretroviral therapy (HAART). Serum hepatitis B viral markers were measured. An antibody level of 10 miu/ml was defined as a protective antibody level. Only one out of 69 children (1%) had a protective antibody level. We concluded that despite the history of hepatitis B immunization and despite evidence of immune recovery after HAART, most HIV-infected children are still susceptible to HBV infection Elsevier Ltd. All rights reserved. Keywords: Hepatitis B virus (HBV); Human immunodeficiency virus (HIV); Protective antibody 1. Introduction Experience from studies involving hematopoietic stem cell transplantation (HSCT) recipients revealed that protective immunity to diseases preventable by routine vaccination was lost over time following transplantation. Furthermore, adoptive transfer of immunity from donors to recipients after allogeneic transplantation was not sufficient to prevent this decline. Systematic re-immunization was necessary at appropriate time intervals following transplantation to re-establish immunity [1]. Consequently, the Centers for Disease Control and Prevention (CDC), the Infectious Disease Society of America, and the American Society of Blood and Marrow Transplantation have published evidence-based recommendations, including re-immunization schedules, Corresponding author at: Division of Infectious Disease, Department of Pediatrics, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand. Tel.: ; fax: address: tputhana@mail.med.cmu.ac.th (T. Puthanakit). for preventing of opportunistic infections among HSCT patients [2]. Human immunodeficiency virus (HIV) infection destroys CD4 cells which provide critical help to B cells in the production of antibodies against T cell-dependent antigens and in the differentiation of B cells into memory cells [3]. Previous studies had suggested that combination antiretroviral therapy can stop CD4 cell attrition and at least partially restore the immune system [4]. This restoration may include immune responses to childhood vaccines. The current World Health Organization recommendations for immunization of children with known or suspected HIV infection is based on the degree of HIV-induced immunosuppression [5]. But guidelines for HIV-infected children with immune recovery after highly active antiretroviral therapy (HAART) have not yet been established. Hepatitis B virus (HBV) infection is a major public health problem in Thailand. The estimated prevalence of HBV carriage is 8 12% in males and 4 8% in females [6]. There is also a high prevalence of 1 2% of HIV infection among X/$ see front matter 2006 Elsevier Ltd. All rights reserved. doi: /j.vaccine
2 3096 S. Siriaksorn et al. / Vaccine 24 (2006) pregnant women [7]. HBV co-infection with HIV is common because both viruses have same modes of transmission. HIVinfected homosexual men co-infected with HBV have been reported to have a higher progression rate to chronic disease, a higher degree of HBV replication with resulting increased risk of transmission, and a lower rate of serum hepatitis B e antigen (HBeAg) loss compared to healthy persons [8,9]. Immunization is an important public health measure to prevent HBV infection. Since 1992, the Thai Ministry of Public Health has included hepatitis B vaccination in its nationwide Expanded Program on Immunization [10].However, the standard immunization schedule with three doses of HBV vaccine has been associated with a lower seroconversion rate in HIV-infected children compared to non HIVinfected group (40 78% and 92 97%, respectively) [11 15]. A study in Thailand revealed the seroconversion rate at 6 months after vaccination to be 71.4% in HIV-infected infants compared to 91.9% in the non-hiv-infected group [14]. Furthermore, a more rapid serum antibody decline has also been reported. At 13 months after vaccination, protective antibody level was detected in only 42% of HIV-infected children who had seroconverted after primary series [13]. Zuin et al. had shown that the prevalence of protective antibody level in HIVinfected children declined from 77.8 to 23.1% within 2 years after vaccination, whereas that in a non-hiv-infected group remained above 90% [15]. The introduction of HAART has resulted in prolonged survival of HIV-infected children. However, information about the long-term persistence of antibody to hepatitis B surface antigen (anti-hbs Ab) after vaccination in these children is limited. Whether re-immunization or additional booster dose is necessary and effective after immune recovery remains unknown. Because of low seroconversion rate and rapid antibody decline over time, we hypothesized that most HIVinfected children have a non-protective antibody level and consequently have increased susceptibility to breakthrough HBV infection even after the commencement of HAART. Thus, we conducted this study to determine the prevalence of HBV protective antibody in HIV-infected children with immune recovery after HAART. 2. Patients and methods This cross-sectional study was conducted at Chiang Mai University hospital in March The study protocol was approved by the research ethics committee of Chiang Mai University. Written informed consent was obtained from each child s parent or guardian before enrollment. The inclusion criteria were HIV-infected children who: (1) were more than 5 years of age, (2) had been severely immunosuppressed (CD4 cell < 15%), (3) received HAART which was defined as 3 antiretroviral drugs in a regimen in which 1 of antiretroviral drugs was a protease inhibitor or a nonnucleoside reverse-transcriptase inhibitor, (4) had shown evidence of immune recovery for at least 3 months after HAART (CD4 cell 15%), and (5) had had their HBV immunization documented in the medical records or by interview with caregivers. The exclusion criteria were children who: (1) received immunosuppressive agents within 3 months, or (2) received blood component transfusion within 6 months prior to the study. Past illnesses and immunization data were collected by medical record review and caregiver interview. The clinical stage of disease was determined according to the 1994 US CDC revised classification [16]. The serial CD4 cell count and plasma HIV RNA level were routinely performed in HIV-infected children at the beginning of HAART and at every 3 6 months afterward. CD4 cell counts and percentages were assessed with the use of a FACSCount apparatus (Becton-Dickinson). Plasma HIV RNA levels were measured by the Roche Ultrasensitive Amplicor assay, version 1.5 (Roche). The most recent values of CD4 cell count and plasma HIV RNA level obtained within 3 months before or after the study were designated as current values in this report. Blood samples were collected for HBV profiles. Serum hepatitis B surface antigen (HBsAg), anti-hbs Ab, and antibody to hepatitis B core antigen (anti-hbc Ab) were measured by HBsAg (V2), AUSAB, and CORE TM, enzymelinked immunoassay diagnostic kits (Abbott Laboratories, Abbott Park, IL, USA), respectively. The amount of anti-hbs Ab was determined using the calibration curve generated by AxSYM AUSAB. An antibody level of 10 miu/ml was defined as a protective antibody level. The children who had either HBsAg or anti-hbc Ab were considered to have natural HBV infection [17]. The chronic carrier state of children with HBsAg and no anti-hbs Ab was confirmed by persisting serum HBsAg 6 months after the first test [17]. The liver function profiles of these carriers were done to determine whether active hepatitis was present. Statistical analyses were performed with Statistical Package for Social Science version 11.5 software (SPSS Inc., Chicago, IL, USA). 3. Results Seventy-five HIV-infected children were enrolled. The demographic data and immunological and viral status of the participants are shown in Table 1. There were 39 boys and 36 girls. The mean age was 9.6 years (S.D. = 2.5). Half of them (51%) were in CDC clinical category C. Means of CD4 cell percentage and plasma HIV RNA level prior to initiation of HAART were 5% (S.D. = 5) and 5.4 log 10 copies/ml (S.D. = 0.4), respectively. Means of current CD4 cell percentage and plasma HIV RNA level were 25% (S.D. = 5) and 1.8 log 10 copies/ml (S.D. = 0.5), respectively. There were only six children (8%) whose current HIV RNA levels were more than 1.7 log 10 copies/ml. The mean age at which HAART was prescribed was 7.6 years (S.D. = 2.5). They had been treated with HAART for an average of 2 years and
3 S. Siriaksorn et al. / Vaccine 24 (2006) Table 1 Characteristics of study participants (N = 75) Characteristics Data Age (years) 9.6 ± 2.5 Male (gender) 39 (52) CDC clinical category N 7 (9) A 15 (20) B 15 (20) C 38 (51) CD4 cell percentage prior to HAART (%) 5 ± 5 Plasma HIV RNA level prior to HAART 5.4 ± 0.4 (log 10 copies/ml) HAART regimen Nevirapine-based a 35 (47) Efavirenz-based a 35 (47) Protease inhibitor-based a 5 (6) Current CD4 cell percentage (%) 25 ± 5 Current plasma HIV RNA level (log 10 copies/ml) 1.8 ± 0.5 Age at which HAART was prescribed (years) 7.6 ± 2.5 Duration of HAART (months) 24.0 ± 4.4 Duration of documented severe immune suppression 12.0 ± 7.6 (CD4 cell <15%) (months) Duration of documented immune recovery (CD ± 6.7 cell 15%) (months) Note: Data are shown in number (%) or mean ± S.D. a A combination of two nucleotide reverse transcriptase inhibitors with nevirapine, efavirenz, or a protease inhibitor. their CD4 cell percentage had been 15% for more than 1 year. The HBV immunization status was documented by medical record in 55 children (73%) and by history in 20 children (27%). There was no difference in baseline characteristics between the two groups except that the former group have received HAART slightly longer (24.6 ± 4.4 months versus 22.2 ± 4.2 months, p = 0.033). Fifty-three of 55 children whose immunization status was documented by medical record received a three-dose regimen (at birth, 2 months, and 6 months of age), while the remaining two children received a four-dose regimen (at birth, 2 months, 6 months, and 12 months of age). As Fig. 1 indicates, 69 children (92%) did not have evidence of natural HBV infection. Only one (1%) had protective level of anti-hbs Ab. Fifteen children (20%) had low levels of anti-hbs Ab and 53 children (71%) had undetectable levels of anti-hbs Ab. Among six children who had evidence of natural HBV infection, two (3%) also had persisting HBsAg and were classified as chronic HBV carriers. They had no history of clinical hepatitis. Current liver function profiles were within normal limits. They had no history of blood transfusion. There was no information on the HBV status of the mothers of these two children. Two of the remaining four (3%) developed naturally acquired immunity while another two did not. Among three children who had protective antibody levels, the one who had vaccine-induced immunity had a lower anti-hbs Ab level than the other two children who had natural infection (11.1 miu/ml versus 25.5 and 1000 miu/ml). Maternal hepatitis B status was available in only three children. Two of the mothers had positive HBsAg and the newborns were given hepatitis B vaccine and hepatitis B immune globulin (HBIG) within 12 h after birth. Neither of them acquired HBV infection through perinatal transmission. Nine children (12%) had history of blood transfusions but their most recent transfusions were more than 6 months prior to the study. None of them acquired HBV infection through blood transfusion. Of the two children who received a four-dose regimen of HBV immunization, one had an undetectable anti-hbs Ab level while the other had evidence of breakthrough infection with a low anti-hbs Ab level. 4. Discussion In the present study, we found that the prevalence of HBV protective antibody in HIV-infected children with immune recovery after HAART was as low as 1%. The result confirmed our hypothesis that most HIV-infected children with immune recovery after HAART are susceptible to HBV infection despite HBV immunization during the infancy period. Further study is required to determine whether reimmunization or additional booster dose will result in protective levels of anti-hbs Ab in this population. In our study, the percentage of children who had anti-hbs Ab 10 miu/ml was found to be 4% (three children), while two of these three children developed naturally acquired immunity. In a study in healthy Italian children who received a three-dose primary HBV immunization during infancy period, the anti-hbs Ab remained above protective level in 64% 10 years after the immunization [18]. The difference between the persistence of HBV protective antibody among HIV-infected and healthy children may be explained either by low seroconversion rate to the primary series (primary vaccine failure) [13 15] or by the more rapid rate of antibody decline (secondary vaccine failure) [13 15]. Of the 69 children in this study who did not have evidence of natural HBV infection, only one developed a protective anti-hbs Ab level from immunization. All six children who had shown evidence of natural HBV infection had no history of clinical hepatitis. Two of these six (33%) had turned into chronic carrier stage. This supported the finding from a previous study which demonstrated that HIV-infected subjects co-infected with HBV had a higher progression rate to chronic disease [8]. Factors that might affect immune responses to primary HBV immunization in HIV-infected children have been studied [11,13 15]. The CD4 cell count, clinical category, and age at first vaccination were not significantly different between children who were able to mount an immune response to HBV vaccine and those who were not. In our study, there was only one child who had vaccine-induced immunity, so
4 3098 S. Siriaksorn et al. / Vaccine 24 (2006) Fig. 1. The hepatitis B virus serological outcomes. the factors affecting immune response to HBV vaccine cannot be addressed. Findings in immunocompetent persons suggested that routine boosters were not necessary due to anamnestic antibody responses that followed exposure to HBV, even when antibodies had declined to low or undetectable levels [19,20]. This finding may not be applicable to immunocompromised persons. In HSCT recipients, the CDC recommended HBV re-immunization with the usual dosage of vaccine at 12, 14, and 24 months after transplantation, and post-vaccination anti-hbs Ab testing at 1 2 months after the third dose. Persons who do not respond to this primary vaccine series should complete a second three-dose series [2]. In studies in HIV-infected adults the majority of whom were receiving HAART, the response rates to HBV immunization were 34 47% [21,22]. Whether one should apply similar measures in HIV-infected children whose immune system had been restored by HAART should be further investigated. There were several limitations in this study. First, because of the cross-sectional study design, there was no information on the baseline primary antibody response to HBV vaccine in order to address the issue of primary versus secondary vaccine failure. Secondly, 27% of the past HBV immunization was determined by history taking. Normally in Thailand, vaccination history was documented in the medical record and in the patient s copy of the vaccination book. The medical records were kept only for 5 years after last visit. Despite efforts to contact the children s health care providers and family members, we could not obtain either medical records or vaccination books for the infancy period of these children. In conclusion, we have documented low prevalence of HBV protective antibody in HIV-infected children with immune recovery after HAART, despite HBV immunization during infancy. Further study is required to determine whether re-immunization or additional booster dose will protect these children against HBV infection. Acknowledgements This study was supported by the Faculty of Medicine, Chiang Mai University and the Thailand Research Fund of the Royal Thai Government. The authors thank John McDemed, PhD for help with the manuscript.
5 S. Siriaksorn et al. / Vaccine 24 (2006) References [1] Singhal S, Mehta J. Reimmunization after blood or marrow stem cell transplantation. Bone Marrow Transpl 1999;23(7): [2] Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. MMWR Recomm Rep 2000;49(RR-10):1 125, CE1-7. [3] Obaro SK, Pugatch D, Luzuriaga K. Immunogenicity and efficacy of childhood vaccines in HIV-1-infected children. Lancet Infect Dis 2004;4(8): [4] Landay AL, Bettendorf D, Chan E, Spritzler J, Schmitz JL, Bucy RP, et al. Evidence of immune reconstitution in antiretroviral drugexperienced patients with advanced HIV disease. AIDS Res Hum Retrov 2002;18(2): [5] Moss WJ, Clements CJ, Halsey NA. Immunization of children at risk of infection with human immunodeficiency virus. Bull World Health Organ 2003;81(1): Epub 2003 March 11. [6] Lolekha S. Hepatitis B in Thailand: epidemiology, prevention and control. In: Zuckerman A, editor. Hepatitis B in the Asian-Pacific region. London: Royal College of Physicians of London; p [7] Results of HIV Sero-surveillance, Thailand (round 1 22) [Accessed at [8] Gilson RJ, Hawkins AE, Beecham MR, Ross E, Waite J, Briggs M, et al. Interactions between HIV and hepatitis B virus in homosexual men: effects on the natural history of infection. AIDS 1997;11(5): [9] Horvath J, Raffanti SP. Clinical aspects of the interactions between human immunodeficiency virus and the hepatotropic viruses. Clin Infect Dis 1994;18(3): [10] Poovorawan Y, Theamboonlers A, Vimolket T, Sinlaparatsamee S, Chaiear K, Siraprapasiri T, et al. Impact of hepatitis B immunisation as part of the EPI. Vaccine 2000;19(7 8): [11] Arrazola MP, de Juanes JR, Ramos JT, Aragon AJ, Garcia de Codes A. Hepatitis B vaccination in infants of mothers infected with human immunodeficiency virus. J Med Virol 1995;45(3): [12] Rutstein RM, Rudy B, Codispoti C, Watson B. Response to hepatitis B immunization by infants exposed to HIV. AIDS 1994;8(9): [13] Scolfaro C, Fiammengo P, Balbo L, Madon E, Tovo PA. Hepatitis B vaccination in HIV-1-infected children: double efficacy doubling the paediatric dose. AIDS 1996;10(10): [14] Thaithumyanon P, Punnahitananda S, Praisuwanna P, Thisyakorn U. Ruxrungtham K. Antibody response to hepatitis B immunization in infants born to HIV-infected mothers. J Med Assoc Thai 2002;85(3): [15] Zuin G, Principi N, Tornaghi R, Paccagnini S, Re M, Massironi E, et al. Impaired response to hepatitis B vaccine in HIV-infected children. Vaccine 1992;10(12): [16] 1994 Revised Classification System for Human Immunodeficiency Virus Infection in Children Less Than 13 Years of Age [Accessed at htm]. [17] Hochman JA, Balistreri WF. Chronic viral hepatitis: always be current! Pediatr Rev 2003;24(12): [18] Zanetti AR, Mariano A, Romano L, D Amelio R, Chironna M, Coppola RC, et al. Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study. Lancet 2005;366(9494): [19] Wang RX, Boland GJ, van Hattum J, de Gast GC. Long-term persistence of T cell memory to HBsAg after hepatitis B vaccination. World J Gastroenterol 2004;10(2): [20] Watson B, West DJ, Chilkatowsky A, Piercy S, Ioli VA. Persistence of immunologic memory for 13 years in recipients of a recombinant hepatitis B vaccine. Vaccine 2001;19(23 24): [21] Tedaldi EM, Baker RK, Moorman AC, Wood KC, Fuhrer J, McCabe RE, et al. Hepatitis A and B vaccination practices for ambulatory patients infected with HIV. Clin Infect Dis 2004;38(10): [22] Fonseca MO, Pang LW, Cavalheiro NdP, Barone AA, Lopes MH. Randomized trial of recombinant hepatitis B vaccine in HIV-infected adult patients comparing a standard dose to a double dose. Vaccine 2005;23(22):
Japanese encephalitis vaccination in HIV-infected children with immune recovery after highly active antiretroviral therapy
Available online at www.sciencedirect.com Vaccine 25 (2007) 8257 8261 Japanese encephalitis vaccination in HIV-infected children with immune recovery after highly active antiretroviral therapy Thanyawee
More informationEvidence of protection against clinical and chronic hepatitis B infection 20 year after infant vaccination in Thailand
Evidence of protection against clinical and chronic hepatitis B infection 20 year after infant vaccination in Thailand http://waipra.blogspot.com/2011/02/9.html Burden of disease in Thailand Liver diseases
More informationAre booster immunisations needed for lifelong hepatitis B immunity?
Are booster immunisations needed for lifelong hepatitis B immunity? European Consensus Group on Hepatitis B immunity, following meeting in Florence in October 1998 To date there are no data to support
More informationResponse to Measles, Mumps, and Rubella Revaccination in HIV-Infected Children with Immune Recovery after Highly Active Antiretroviral Therapy
MAJOR ARTICLE HIV/AIDS Response to Measles, Mumps, and Rubella Revaccination in HIV-Infected Children with Immune Recovery after Highly Active Antiretroviral Therapy Linda Aurpibul, 1 Thanyawee Puthanakit,
More informationPrevention and control of hepatitis B with combined vaccines, and birth dose vaccination
Prevention and control of hepatitis B with combined vaccines, and birth dose vaccination Prof. Yong Poovorawan Center of Excellence in Clinical Virology Faculty of Medicine Chulalongkorn University The
More informationHepadnaviridae family (DNA) Numerous antigenic components Humans are only known host May retain infectivity for more than 7 days at room temperature
Hepatitis B Epidemic jaundice described by Hippocrates in 5th century BC Jaundice reported among recipients of human serum and yellow fever vaccines in 1930s and 1940s Australia antigen described in 1965
More informationHBV-2 Group: neonates born to HBsAg+ and HBeAg+ mothers who received a 4-dose vaccination regimen (Part of
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationViral Hepatitis Diagnosis and Management
Viral Hepatitis Diagnosis and Management CLINICAL BACKGROUND Viral hepatitis is a relatively common disease (25 per 100,000 individuals in the United States) caused by a diverse group of hepatotropic agents
More informationHepatitis B vaccination: a completed schedule enough to control HBV lifelong? MILAN, ITALY November 2011
Viral Hepatitis Prevention Board Hepatitis B vaccination: a completed schedule enough to control HBV lifelong? MILAN, ITALY 17-18 November 2011 Objectives To review long-term efficacy of hepatitis B vaccine
More informationChapter 5 Serology Testing
Chapter 5 Serology Testing 49 50 This page intentionally left blank. Diagnostic Tests for Hepatitis B Virus (HBV) Diagnosis of HBV infection (acute vs. chronic) is based on clinical, laboratory, and epidemiologic
More informationHBV vaccination: Optimizing coverage and efficacy. Alex Vorsters, Pierre Van Damme Viral Hepatitis Prevention Board
HBV vaccination: Optimizing coverage and efficacy. Alex Vorsters, Pierre Van Damme Viral Hepatitis Prevention Board 2 nd Hepatitis Cure and Eradication Meeting 11 12 November 2015 Declaration of Interest
More informationSEROLOGICAL SURVEY OF VIRAL HEPATITIS A, B, AND C AT THAI CENTRAL REGION AND BANGKOK: A POPULATION BASE STUDY
SEROLOGICAL SURVEY OF VIRAL HEPATITIS A, B, AND C AT THAI CENTRAL REGION AND BANGKOK: A POPULATION BASE STUDY Winai Ratanasuwan 1, Areeua Sonji 1, Surapee Tiengrim 2, Wichai Techasathit 1 and Surapol Suwanagool
More informationUpdate of the universal vaccination programme in Italy
Update of the universal vaccination programme in Italy Progress in the prevention and control of hepatitis B in Italy, 12 years after the implementation of universal vaccination. Duration of immunity and
More informationHepatitis Case Investigation
* indicates required fields Does patient also have: Hepatitis Case Investigation West Virginia Electronic Disease Surveillance System Division of Surveillance and Disease Control Infectious Disease Epidemiology
More informationSeroprotection after Hepatitis B Vaccination among Newborn Infants: a Review
Center for Global Health Seroprotection after Hepatitis B Vaccination among Newborn Infants: a Review Rania Tohme, MD, MPH Team Lead Global Immunization Division, US CDC Viral Hepatitis Prevention Board
More informationAN ECONOMIC EVALUATION OF UNIVERSAL INFANT VACCINATION STRATEGIES AGAINST HEPATITIS B IN THAILAND: AN ANALYTIC DECISION APPROACH TO COST-EFFECTIVENESS
AN ECONOMIC EVALUATION OF UNIVERSAL INFANT VACCINATION STRATEGIES AGAINST HEPATITIS B IN THAILAND: AN ANALYTIC DECISION APPROACH TO COST-EFFECTIVENESS Thosporn Vimolket 1 and Yong Poovorawan 2 1 Department
More informationMicropathology Ltd. University of Warwick Science Park, Venture Centre, Sir William Lyons Road, Coventry CV4 7EZ
www.micropathology.com info@micropathology.com Micropathology Ltd Tel 24hrs: +44 (0) 24-76 323222 Fax / Ans: +44 (0) 24-76 - 323333 University of Warwick Science Park, Venture Centre, Sir William Lyons
More informationManagement of Hepatitis B - Information for primary care providers
Management of Hepatitis B - Information for primary care providers July 2018 Chronic hepatitis B (CHB) is often a lifelong condition. Not everyone infected needs anti-viral therapy. This document outlines
More informationHepatitis B (HBV) vaccine: need for a booster injection? VHPB, Kyiv 2004
Hepatitis B (HBV) vaccine: need for a booster injection? VHPB, Kyiv 2004 Information for the Development of Immunization Policy 2002 update (WHO/V&B/02.28, printed: March 2003) The priorities for hepatitis
More informationGuideline on the use of Hepatitis A&B Immunisations for Immunocompromised and Immunocompetent Hepatology Patients
Guideline on the use of Hepatitis A&B Immunisations for Immunocompromised and Immunocompetent Hepatology Patients WOMEN AND CHILDREN S DIRECTORATE ACUTE SERVICES DIVISION GUIDELINES TITLE Guideline on
More informationLong term hepatitis B vaccine in infants born to hepatitis B e antigen positive mothers
Archives of Disease in Childhood 1997;77:F47 F51 F47 Viral Hepatitis Research Unit Chulalongkorn University Hospital, Bangkok, Thailand Y Poovorawan Department of Paediatrics S Sanpavat S Chumdermpadetsuk
More informationPERINATAL HEPATIDES AND HUMAN IMMUNODEFICIENCY VIRUS (HIV) Pamela Palasanthiran Staff Specialist, Paediatric Infectious Diseases
PERINATAL HEPATIDES AND HUMAN IMMUNODEFICIENCY VIRUS (HIV) Pamela Palasanthiran Staff Specialist, Paediatric Infectious Diseases Viruses in July (ViJ), 2004 Overview Epidemiology Perinatal transmission
More informationORIGINAL ARTICLE Hepatitis B seroepidemiology and booster vaccination in pre-clinical medical students in a Malaysian university
Malaysian J Pathol 2018; 40(3) : 295 302 ORIGINAL ARTICLE Hepatitis B seroepidemiology and booster vaccination in pre-clinical medical students in a Malaysian university Siti Norlia OTHMAN, Zetti ZAINOL
More informationpatients with blood borne viruses Controlled Document Number: Version Number: 4 Controlled Document Sponsor: Controlled Document Lead:
CONTROLLED DOCUMENT Procedure for the management of patients with blood borne viruses CATEGORY: CLASSIFICATION: PURPOSE Controlled Document Number: Version Number: 4 Controlled Document Sponsor: Controlled
More informationEAST LONDON INTEGRATED CARE
CITY & HACKNEY ELIC EAST LONDON INTEGRATED CARE MANAGEMENT OF CHRONIC HEPATITIS B IN PRIMARY CARE Chronic Hepatitis B virus (HBV) is an important public health problem globally and a leading cause of liver
More informationEvolution of Hepatitis B Serological Markers in HIV-Infected Patients Receiving Highly Active Antiretroviral Therapy
MAJOR ARTICLE HIV/AIDS Evolution of Hepatitis B Serological Markers in HIV-Infected Patients Receiving Highly Active Antiretroviral Therapy Wang-Huei Sheng, 1,3,6,a Jia-Horng Kao, 5,a Pei-Jer Chen, 5 Li-Ming
More informationINTERPRETING HEPATITIS B SEROLOGY
INTERPRETING HEPATITIS B SEROLOGY RECOMMENDED WORDING FOR NATIONAL LABORATORIES TO REPORT HEPATITIS B DIAGNOSTIC TEST RESULTS THIS DOCUMENT HAS BEEN ENDORSED BY: Australasian Society for HIV Medicine,
More informationHepatitis B and Hepatitis B Vaccine
Hepatitis B and Epidemiology and Prevention of Vaccine- Preventable Diseases Note to presenters: Images of vaccine-preventable diseases are available from the Immunization Action Coalition website at http://www.vaccineinformation.org/photos/index.asp
More informationPerinatal Hepatitis b Prevention
Perinatal Hepatitis b Prevention Purpose 2 The primary goal of the Perinatal Hepatitis b Prevention Program (PHBPP) is to identify all pregnant women who are infected with hepatitis b and prevent perinatal
More informationHepatitis B Update. Jorge L. Herrera, M.D. University of South Alabama Mobile, AL. Gastroenterology
Hepatitis B Update Jorge L. Herrera, M.D. University of South Alabama Mobile, AL Deciding Who to Treat Is hepatitis B a viral disease or a liver disease? Importance of HBV-DNA Levels in the Natural History
More informationConfirmed (Laboratory Tests) Serum positive for IgM anti-hbc or, hepatitis B surface antigen (HbsAg).
Hepatitis B Hepatitis B is a liver disease that results from infection with the Hepatitis B virus. It can range in severity from a mild illness lasting a few weeks to a serious, lifelong illness. Hepatitis
More informationSummary of Seroprotection after Recombinant Hepatitis B Vaccine Administered to Newborn Infants (defined as the first 30 days of Life) Background:
Prepared by: TV Murphy, MD, September 16, 2016 Summary of Seroprotection after Recombinant Hepatitis B Vaccine Administered to Newborn Infants (defined as the first 30 days of Life) Background: The primary
More informationThe Alphabet Soup of Viral Hepatitis Testing
The Alphabet Soup of Viral Hepatitis Testing August 18, 2011 Patricia Slev, PhD, DABCC Medical Director, Serologic Hepatitis and Retrovirus Laboratory, ARUP Laboratories Assistant Professor of Pathology,
More informationCITY & HACKNEY ELIC EAST LONDON INTEGRATED CARE MANAGEMENT OF CHRONIC HEPATITIS B IN PRIMARY CARE
CITY & HACKNEY ELIC EAST LONDON INTEGRATED CARE MANAGEMENT OF CHRONIC HEPATITIS B IN PRIMARY CARE Chronic Hepatitis B virus (HBV) is an important public health problem globally and a leading cause of liver
More informationOB Provider Guide to Alaska s Perinatal Hepatitis B Prevention Program
OB Provider Guide to Alaska s Perinatal Hepatitis B Prevention Program Dear Colleague, This letter is to introduce myself and explain the role I play with the Alaska Perinatal Hepatitis B Program. Alaska
More informationHEPATITIS B MANAGEMENT
HEPATITIS B MANAGEMENT Background Chronic Hepatitis B Virus (HBV) infection had an estimated prevalence in Australia of 0.7-0.8% in 2002 (1). Prevalence is highest in people born in much of Asia and Africa
More informationManagement of Chronic Hepatitis B in Asian Americans
Management of Chronic Hepatitis B in Asian Americans Myron J Tong; UCLA, CA Calvin Q. Pan; Mount Sinai, NY Hie-Won Hann; Thomas Jefferson, PA Kris V. Kowdley; Virginia Mason, WA Steven Huy B Han; UCLA,
More informationTest Name Results Units Bio. Ref. Interval
LL - LL-ROHINI (NATIONAL REFERENCE 135091606 Age 24 Years Gender Male 30/8/2017 92800AM 30/8/2017 94631AM 31/8/2017 90306AM Ref By Final HEATITIS A & B VIRUS EVALUATION HEATITIS A ANTIBODY (ANTI HAV),
More informationTest Name Results Units Bio. Ref. Interval
LL - LL-ROHINI (NATIONAL REFERENCE 135091650 Age 49 Years Gender Male 29/8/2017 120000AM 29/8/2017 100248AM 29/8/2017 105306AM Ref By Final HEATITIS, VIRAL, COMREHENSIVE ANEL HEATITIS A ANTIBODY (ANTI
More informationCarrier state and chronic infection state. At-risk populations
John T. Stutts, MD, MPH University of Louisville School of Medicine Department of Pediatrics Division of Pediatric Gastroenterology, Hepatology and Nutrition Carrier state and chronic infection state -
More informationHighly active antiretroviral (ARV) therapy (HAART) has dramatically
ORIGINAL STUDIES Pattern and Predictors of Immunologic Recovery in Human Immunodeficiency Virus-Infected Children Receiving Non-Nucleoside Reverse Transcriptase Inhibitor-Based Highly Active Antiretroviral
More informationSelected Primary-Care Issues in HIV Disease
Perspective Selected Primary-Care Issues in HIV Disease Primary care for HIV-infected patients includes ensuring that eligible patients receive hepatitis B and A virus vaccinations, all women undergo appropriate
More informationMA PERINATAL HEPATITIS B PREVENTION PROGRAM
MA PERINATAL HEPATITIS B PREVENTION PROGRAM Massachusetts Department of Public Health Immunization Program MIAP 2016 1 1 Presenter Disclosure Information I, Theodora Wohler, have been asked to disclose
More informationTime to Eliminate Hepatitis B John W. Ward, M.D. Division of Viral Hepatitis Centers for Disease Control and Prevention
Time to Eliminate Hepatitis B John W. Ward, M.D. Division of Viral Hepatitis Centers for Disease Control and Prevention Division of Viral Hepatitis National Center for HIV/AIDS, Viral Hepatitis, STD, and
More informationLearning Objectives: Hepatitis Update. Primary Causes of Chronic Liver Disease in the U.S. Hepatitis Definition. Hepatitis Viruses.
Learning Objectives: Hepatitis Update ASCLS-Michigan March 31, 2016 Dr. Kathleen Hoag Upon attendance of this seminar and review of material provided, the attendees will be able to: 1. List hepatitis viruses
More informationHIV-HBV coinfection in HIV population horizontally infected in early childhood between
UNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA FACULTY OF MEDICINE HIV-HBV coinfection in HIV population horizontally infected in early childhood between 1987-1990 Supervising professor: Prof. Cupşa Augustin
More informationElimination of Perinatal Hepatitis B Transmission
Elimination of Perinatal Hepatitis B Transmission Trudy V. Murphy, MD Division of Viral Hepatitis NCHHSTP, CDC December 19, 2013 Hep B United and WHIAAPI Webinar Background q Hepatitis B is an infection
More informationHepatitis B. ECHO November 29, Joseph Ahn, MD, MS Associate Professor of Medicine Director of Hepatology Oregon Health & Science University
Hepatitis B ECHO November 29, 2017 Joseph Ahn, MD, MS Associate Professor of Medicine Director of Hepatology Oregon Health & Science University Disclosures Advisory board Gilead Comments The speaker Joseph
More informationSummary of Key Points. WHO Position Paper on Vaccines against Hepatitis B, July 2017
Summary of Key Points WHO Position Paper on Vaccines against Hepatitis B, July 2017 1 Background l HBV is transmitted by exposure of mucosal membranes or non-intact skin to infected blood, saliva, semen
More informationSTATE TDAP VACCINE PROGRAM
STATE TDAP VACCINE PROGRAM CDPH provides free Tdap vaccine for local public health departments. This vaccine then is distributed to clinics through out county. Vaccine to be specifically given to: Woman
More informationEvidence of protection against clinical and chronic hepatitis B infection 20 years after infant vaccination in a high endemicity region
Journal of Viral Hepatitis, 20, 8, 369 375 doi:./j.365-2893.20.032.x Evidence of protection against clinical and chronic hepatitis B infection 20 years after infant vaccination in a high endemicity region
More informationObstetric Complications in HIV-Infected Women. Jeanne S. Sheffield, MD Maternal-Fetal Medicine UT Southwestern Medical School
Obstetric Complications in HIV-Infected Women Jeanne S. Sheffield, MD Maternal-Fetal Medicine UT Southwestern Medical School Obstetric Complications and HIV Obstetric complications are not increased in
More informationHepatitis B vaccine: long-term efficacy, booster policy, and impact of HBV mutants on hepatitis B vaccination programmes
Hepatitis B vaccine: long-term efficacy, booster policy, and impact of HBV mutants on hepatitis B vaccination programmes VHPB meeting, Seville, 11-12 March 2004 Immunization programmes Programmes protect
More informationViral Hepatitis. Dr Melissa Haines Gastroenterologist Waikato Hospital
Viral Hepatitis Dr Melissa Haines Gastroenterologist Waikato Hospital Viral Hepatitis HAV HBV HCV HDV HEV Other viral: CMV, EBV, HSV Unknown Hepatitis A Hepatitis A Transmitted via the faecal-oral route
More informationHepatitis B infection
Hepatitis B infection Kenneth Kabagambe Executive Director The National Organization for People Living with Hepatitis B (NOPLHB Uganda General introduction: Viral hepatitis in Uganda Viruses that affect
More informationPerinatal Hepatitis B Prevention Program. Purpose
Perinatal Hepatitis B Prevention Program Presented by: Carolyn Perry, RN, BSN Purpose 2 The primary goal of the Perinatal Hepatitis B Prevention Program (PHBPP) is to identify all pregnant women who are
More informationToronto Declaration: Strategies to control and eliminate viral hepatitis globally. A call for coordinated action
Toronto Declaration: Strategies to control and eliminate viral hepatitis globally A call for coordinated action Hepatitis B National Action Plan All countries should develop a national and/or regional
More informationHepatitis B Control. Table of Contents
Control Table of Contents 1.0 INTRODUCTION... 1 2.0 GOALS... 1 3.0 DEFINITIONS... 1 4.0 CASE MANAGEMENT... 3 5.0 HEPATITIS B POST- EXPOSURE MANAGEMENT... 4 TABLE 1: HEPATITIS B POST EXPOSURE PROPHYLAXIS...
More informationA Message to Presenters
A Message to Presenters As a healthcare professional speaking on behalf of Bristol-Myers Squibb (BMS), any presentation you make on our behalf must be consistent with the current FDA-approved product labeling
More informationTest Name Results Units Bio. Ref. Interval
LL - LL-ROHINI (NATIONAL REFERENCE 135091608 Age 26 Years Gender Female 30/8/2017 92900AM 30/8/2017 94717AM 31/8/2017 90216AM Ref By Final HEATITIS ACUTE VIRUS CONFIRMATION HEATITIS A ANTIBODY (ANTI HAV),
More informationin pregnancy Document Review History Version Review Date Reviewed By Approved By
GYNAECOLOGY/ ANTENATAL CARE WIRRAL WOMEN & CHILDREN S HOSPITAL Guideline No: Hepatitis B management in pregnancy VERSION 1 AMENDMENTS MADE: N/A DATE OF ISSUE: May 2012 DATE OF REVIEW: May 2015 REVIEW INTERVAL:
More informationDiagnostic Methods of HBV and HDV infections
Diagnostic Methods of HBV and HDV infections Zohreh Sharifi,ph.D Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine Hepatitis B-laboratory diagnosis Detection
More informationThe ABCs of Viral Hepatitis Diagnosis. Ila Singh, M.D., Ph.D. P & S Viral Hepatitis. Hepatitis A, B, C, D, E and G viruses
The ABCs of Viral Hepatitis Diagnosis Ila Singh, M.D., Ph.D. P & S 14-453 is132@columbia.edu Viral Hepatitis Hepatotropic viruses Hepatitis A, B, C, D, E and G viruses Generalized infection plus infection
More informationSAFETY AND IMMUNOGENICITY OF BACILLUS CALMETTE-GUERIN VACCINE IN CHILDREN BORN TO HIV-1 INFECTED WOMEN
SAFETY AND IMMUNOGENICITY OF BACILLUS CALMETTE-GUERIN VACCINE IN CHILDREN BORN TO HIV-1 INFECTED WOMEN Pimolrat Thaithumyanon 1, Usa Thisyakorn 1, Sunti Punnahitananda 1, Pramote Praisuwanna 2 and Kiat
More informationKanokporn Chaiklang 1, Jiraprapa Wipasa 2, Romanee Chaiwarith 1, Jutarat Praparattanapan 1, Khuanchai Supparatpinyo 1,2* Introduction.
Comparison of Immunogenicity and Safety of Four Doses and Four Double Doses vs. Standard Doses of Hepatitis B Vaccination in HIV-Infected Adults: A Randomized, Controlled Trial Kanokporn Chaiklang 1, Jiraprapa
More informationVaccine 28 (2010) Contents lists available at ScienceDirect. Vaccine. journal homepage:
Vaccine 28 (2010) 730 736 Contents lists available at ScienceDirect Vaccine journal homepage: www.elsevier.com/locate/vaccine Persistence of antibodies and immune memory to hepatitis B vaccine 20 years
More informationOriginal Article. Noparat Oniem, M.D., Somnuek Sungkanuparph, M.D.
Original Article Vol. 29 No. 1 Primary prophylaxis for cryptococcosis with fluconazole:- Oniem N & Sungkanuparph S. 5 Primary prophylaxis for cryptococcosis with fluconazole among HIV-infected patients
More informationHepatitis B virus (HBV) infection is an important. Brief Communication
Brief Communication Hepatitis B Virus Infection in Children and Adolescents in a Hyperendemic Area: 15 Years after Mass Hepatitis B Vaccination Yen-Hsuan Ni, MD, PhD; Mei-Hwei Chang, MD; Li-Min Huang,
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Centre for Clinical Practice SCOPE Clinical guideline title: Hepatitis B (chronic): diagnosis and management of chronic hepatitis B in children, young
More informationHepatitis B Treatment Pearls. Agenda
Hepatitis B Treatment Pearls Fredric D. Gordon, MD Vice Chair Dept. of Transplantation and Hepatobiliary Diseases Lahey Hospital & Medical Center Associate Professor of Medicine Tufts Medical School Boston,
More informationViral Hepatitis in Reproductive Health
Viral Hepatitis in Reproductive Health Training Course in Sexual and Reproductive Health Research Geneva 2010 Dr José M Bengoa Dr Pierre Jean Malè Consultants Division of Gastroenterology and Hepatology
More informationThe hexavalent DTaP/IPV/Hib/HepB combination vaccine
The hexavalent DTaP/IPV/Hib/HepB combination vaccine Factsheet for healthcare professionals about the neonatal selective immunisation programme for babies at risk of hepatitis B Background All babies born
More informationHepatitis and pregnancy
Hepatitis and pregnancy Pierre-Jean Malè MD Training Course in Reproductive Health Research WHO Geneva 2008 26.02.2008 Liver disease and pregnancy: three possible etiologic relationship the patient has
More informationThe hexavalent DTaP/IPV/Hib/HepB combination vaccine
The hexavalent combination vaccine Information for registered healthcare practitioners about the neonatal selective immunisation programme for babies at high risk (babies born to hepatitis B positive mothers)
More informationHEPATITIS B INFECTION and Pregnancy. Caesar Mensah Communicable Diseases & Infection Control Specialist, UK June 2011
HEPATITIS B INFECTION and Pregnancy Caesar Mensah Communicable Diseases & Infection Control Specialist, UK June 2011 HEPATITIS B 26/07/2011 What is Hepatitis B? It is inflammation (infection) of the liver
More informationHepatitis B Positive: Care of Mother Policy
Document ID: MATY031 Version: 1.0 Facilitated by: Jo McMullan, CMM Last reviewed: October 2014 Approved by: Maternity Quality Committee Review date: October 2016 Hepatitis B Positive: Care of Mother Policy
More informationYakima Health District BULLETIN
Yakima Health District BULLETIN Volume 12, Issue 4 December, 2013 Overview Prevention of Perinatal Hepatitis B Transmission Perinatal transmission of hepatitis B virus (HBV) is preventable through universal
More informationMutants and HBV vaccination. Dr. Ulus Salih Akarca Ege University, Izmir, Turkey
Mutants and HBV vaccination Dr. Ulus Salih Akarca Ege University, Izmir, Turkey Geographic Distribution of Chronic HBV Infection 400 million people are carrier of HBV Leading cause of cirrhosis and HCC
More informationObstetrics and HIV An Update. Jennifer Van Horn MD University of Utah
Obstetrics and HIV An Update Jennifer Van Horn MD University of Utah Obstetrics and HIV Perinatal transmission Testing Antiretroviral therapy Antepartum management Intrapartum management Postpartum management
More informationHepatitis B Positive: Care of Mother Policy
Document ID: MATY031 Version: 1.0 Facilitated by: Jo McMullan, CMM Issue Date: July 2012 Approved by: Maternity Quality Committee Review date: October 2016 Hepatitis B Positive: Care of Mother Policy Purpose
More informationHBV in HIV Forgotten but not Gone
Activity Code FA376 HBV in HIV Forgotten but not Gone Richard K. Sterling, MD, MSc VCU Hepatology Professor of Medicine Chief, Section of Hepatology Virginia Commonwealth University Learning Objectives
More informationHuman Hepatitis B Immunoglobulin, solution for intramuscular injection.
New Zealand Data Sheet Hepatitis B Immunoglobulin-VF NAME OF THE MEDICINE Human Hepatitis B Immunoglobulin, solution for intramuscular injection. DESCRIPTION Hepatitis B Immunoglobulin-VF is a sterile,
More informationHepatitis B: A Preventable Cause of Liver Cancer. Saira Khaderi MD, MPH Assistant Professor of Surgery Associate Director, Project ECHO June 17, 2016
Hepatitis B: A Preventable Cause of Liver Cancer Saira Khaderi MD, MPH Assistant Professor of Surgery Associate Director, Project ECHO June 17, 2016 Overview Epidemiology HBV and cancer Screening, Diagnosis
More informationuniversal vaccination
Vol. 21No. 2149 8 HB B universal vaccination Blumberg HBs B 40 B HBV HBV HBV HBs WHO 1992 HBV B HB universal vaccination 1997 HB universal vaccination HBV high risk HBV universal vaccination B HBV universal
More informationGive Birth to the End of Hepatitis B
Give Birth to the End of Hepatitis B LiverConnects Feb 14, 2017 Rosalyn Singleton MD MPH Research Physician, ANTHC ris2@cdc.gov risingleton@anthc.org Annie Peterson-Lewis RN State of Alaska Perinatal Hepatitis
More informationCUMULATIVE PERINATAL HIV EXPOSURE, AUSTRALIA. Date
CUMULATIVE PERINATAL HIV EXPOSURE, AUSTRALIA 350 300 250 Number 200 150 100 50 0 1/01/1997 1/01/1998 1/01/1999 1/01/2000 31/12/2000 31/12/2001 31/12/2002 Date July 2004 Reported number of perinatally exposed
More informationTB/HIV/STD Epidemiology and Surveillance Branch. First Annual Report, Dated 12/31/2009
TB/HIV/STD Epidemiology and Surveillance Branch First Annual Report, Dated 12/31/29 This Enhanced Perinatal Surveillance Report is the first annual report generated by the Texas Department of State Health
More informationNational Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Increased Hepatitis C Virus (HCV) Detection in Women of Childbearing Age and Potential Risk for Vertical Transmission - United States
More informationHepatitis C Best Practice Guidelines For Local Health Departments
Hepatitis C Best Practice Guidelines For Local Health Departments LHDs are responsible for investigating and reporting all physician reported cases of acute hepatitis C (HCV). For clients known to have
More informationHIV 101: Overview of the Physiologic Impact of HIV and Its Diagnosis Part 2: Immunologic Impact of HIV and its Effects on the Body
HIV 101: Overview of the Physiologic Impact of HIV and Its Diagnosis Part 2: Immunologic Impact of HIV and its Effects on the Body Melissa Badowski, PharmD, BCPS, AAHIVP Clinical Assistant Professor University
More informationHEPATITIS VIRUSES. Other causes (not exclusively hepatitis v.)also called sporadic hepatitis: HEPATITIS A(infectious hepatitis)
Dept.of Microbiology/Virology Assist.prof. Shatha F. Abdullah HEPATITIS VIRUSES Medically important hepatitis v. (liver)are: 1.HAV 2.HBV 3.HCV 4.HDV 5.HEV 6.HGV Other causes (not exclusively hepatitis
More informationHEPATITIS B: are escape mutants of concern?
VACCINATION: AN EVOLUTIONARY ENGINE FOR SPECIES? Fondation Mérieux Conference Centre Veyrier-du-Lac, France November 25-27, 2013 HEPATITIS B: are escape mutants of concern? Alessandro ZANETTI Department
More informationHBV : Structure. HBx protein Transcription activator
Hepatitis B Virus 1 Hepatitis B Virus 2 Properties of HBV a member of the hepadnavirus group Enveloped, partially double-stranded DNA viruses, smallest DNA virus Replication involves a reverse transcriptase
More informationChapter 2 Hepatitis B Overview
Chapter 2 Hepatitis B Overview 23 24 This page intentionally left blank. HEPATITIS B OVERVIEW Hepatitis B Virus The hepatitis B virus (HBV) belongs to the Hepadnaviridae family and is known to cause both
More informationHepatitis B vaccination in Haemodialysis Patients: The Impact of Local Endemicity
1 Hepatitis B vaccination in Haemodialysis Patients: The Impact of Local Endemicity Dr. Salwa Ibrahim, MD MRCP Assistant Professor of Nephrology Cairo University, Egypt Patients on hemodialysis therapy
More informationEpatite B: fertilità, gravidanza ed allattamento, aspetti clinici e terapeutici. Ivana Maida
Epatite B: fertilità, gravidanza ed allattamento, aspetti clinici e terapeutici Ivana Maida Positivity for HBsAg was found in 0.5% of tested women In the 70s and 80s, Italy was one of the European countries
More informationHEPATITIS B: Edina Amponsah-Dacosta. Post-Vaccination Surveillance JEFFREY MPHAHLELE. On behalf of. Head
HEPATITIS B: Post-Vaccination Surveillance Edina Amponsah-Dacosta On behalf of Head JEFFREY MPHAHLELE South African Vaccination and Immunisation Centre Co-Director WHO Rotavirus Regional Reference Laboratory
More informationEliminating Chronic Hepatitis B Disparities among Asian Pacific Islanders: A Model for Transforming Public Health in the Pacific
Eliminating Chronic Hepatitis B Disparities among Asian Pacific Islanders: A Model for Transforming Public Health in the Pacific Augustina Manuzak, MD, MPH, PhD Augustina.manuzak@doh.hawaii.gov 10/10/2012
More informationSCCPS Scientific Committee Position Paper on HPV Vaccination
SCCPS Scientific Committee Position Paper on HPV Vaccination Adapted from Joint Statement (March 2011) of the: Obstetrical & Gynaecological Society of Singapore (OGSS) Society for Colposcopy and Cervical
More informationHow to treat HCV-HBV co-infection?
How to treat HCV-HBV co-infection? Robert Flisiak Department of Infectious Diseases and Hepatology Medical University of Białymstoku Paris Hepatology Conference, 14-15 january 219 Conflict od interest
More information